Overview / Abstract: |
Target Audience Nephrologists and primary care providers. The secondary audiences are endocrinologists, cardiologists, specialists in internal medicine (MDs and DOs), nurse practitioners, physician assistants, nurses, and pharmacists. Learning Objectives Upon completion of this activity, participants should be better able to: Apply the evidence-based indications and clinical support for treatment with SGLT2 inhibitors to slow the decline of renal function |
Expiration |
Jun 10, 2022 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
0.75 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty Dr. Richard S. Beaser*† Kamyar Kalantar-Zadeh, MD, MPH, PhD Muthiah Vaduganathan, MD, MPH |
Sponsors / Supporters / Grant Providers |
AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company. |
Keywords / Search Terms |
Relias LLC Relias LLC., Kidney Disease,Chronic Free CE CME |